Methylation modifications in other of the identified genes (PCDH20, CDEB, KCNQ1, MCF2L, LTB4R and PRODH)41–44 have been described in carcinomas but their role in the pathogenesis of leiomyosarcoma progression has not been reported (apart from PCDH2 and PRODH45), and should be further explored. This evidence concerns the gene MCF2L and carcinoma.